Jaban M Moore alias Dr. Biofilm Brainfog

Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Candida overgrowth is the primary missed root cause for fatigue, bloating, sugar cravings, and brain fog, masquerading as stress or aging..

Candida overgrowth is the primary missed root cause for fatigue, bloating, sugar cravings, and brain fog, masquerading as stress or aging.

Supports

Some clinical and mechanistic literature suggests that overgrowth of Candida species can be associated with gastrointestinal symptoms such as bloating and abdominal discomfort. ^{[4][10][11][12]} Reviews on small intestinal fungal overgrowth (SIFO) describe abnormal fungal proliferation (often Candida) presenting with non‑specific GI symptoms like bloating, abdominal pain, and diarrhea, especially in people with clear risk factors such as acid suppression, motility disorders, or immunosuppression. ^[7] These reviews indicate that Candida overgrowth can be one contributor to GI symptoms in selected patients, not a general population mechanism. In invasive or clearly defined mucosal candidiasis (for example, candidemia or oral/vaginal candidiasis), systemic symptoms like fatigue, malaise, or cognitive dullness can occur as part of serious infection, but this is a very different context from “missed” overgrowth in otherwise healthy people. contradicts

In their own wordsWatch sourceArchived copy

“Candida is one of the most missed root causes I come across, and it rarely shows up as an obvious yeast infection. More often it looks like the fatigue, bloating, sugar cravings, and brain fog people have been told is just stress or getting older.”

Rule: RSMo § 331.010(1)

See every doc bro who says they can treat or advise on Candida

Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Standard antifungal cleanses fail because Candida builds biofilms; treatment requires rebuilding good bacteria and supporting cleanup organs to prevent rebound. as within their scope of practice.

Standard antifungal cleanses fail because Candida builds biofilms; treatment requires rebuilding good bacteria and supporting cleanup organs to prevent rebound.

Supports

High-quality mechanistic and translational evidence shows that Candida commonly forms biofilms and that biofilm-associated Candida is much more resistant to standard antifungal drugs than planktonic cells, contributing to treatment failure and recurrence of infection.^{[11][12][13][14][15][17][18][19][20][21][22][25]} Clinical and guideline-oriented reviews note that device-associated Candida biofilm infections (e.g., on catheters or prostheses) often require removal of the colonized device because available systemic antifungals alone rarely eradicate the biofilm, which is consistent with the idea that biofilms can undermine standard therapy.^[22][21] Experimental and translational literature supports the concept of developing targeted anti-biofilm strategies (including novel agents, combinations, and delivery systems) to improve outcomes, which indirectly supports the claim that biofilm biology is a meaningful factor when designing effective treatment regimens for Candida infections.^{[6][14][15][22][24][25]}

Contradicts

The influencer’s further claim that treatment of Candida biofilm-related infection “requires” rebuilding good bacteria and supporting cleanup organs (liver, kidneys, lymph, etc.) to prevent rebound is not supported by high-quality clinical trials, systematic reviews, or major guidelines; these approaches are largely speculative and based on general wellness concepts rather than Candida-specific evidence. No major infectious disease or nutrition guideline in the provided index papers recommends microbiome-rebuilding cleanses or organ-detox protocols as necessary components of standard Candida treatment. Evidence-based frameworks like GRADE emphasize that high-quality recommendations must be grounded in robust data; organ-support and “good bacteria restoration” for Candida biofilms do not meet these thresholds. Current biofilm-focused reviews and translational perspectives instead emphasize accurate diagnosis, species identification, antifungal susceptibility testing, source control (e.g., device removal), and appropriate antifungal selection/dosing as the main evidence-backed strategies, rather than generalized cleanses or detox regimens.^{[14][15][16][17][21][22]}

Mainstream view

Mainstream medical and scientific opinion recognizes that Candida biofilms are a major mechanism of antifungal resistance and treatment failure, especially on indwelling medical devices and in recurrent mucosal infections; this is now a well-established part of the pathophysiology of candidiasis.^{[11][14][15][16][17][19][22][25]} Standard care focuses on evidence-based antifungal therapy (azoles, echinocandins, polyenes) guided by susceptibility testing, plus source control such as removal of colonized devices when biofilms are present, and on addressing underlying risk factors (immunosuppression, diabetes, antibiotic exposure) rather than on nonvalidated “Candida cleanses.”^{[14][15][16][19][21][22]} While the microbiome and host organ function are recognized as important for overall health, major guidelines and high-quality reviews do not endorse microbiome cleanses, liver/kidney detox protocols, or generalized “cleanup organ support” as required elements of Candida biofilm treatment; such practices remain outside mainstream, evidence-based management.

In their own wordsWatch sourceArchived copy

“Most cleanses hammer the yeast with antifungals for a couple weeks, symptoms improve, and then everything comes roaring back. That rebound happens because candida builds biofilms to protect itself, and because starving it does nothing if you never rebuild the good bacteria or support the organs doing the cleanup.”

Rule: RSMo § 331.010(1)

See every doc bro who says they can treat or advise on Candida

Jaban M Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Aggressive antifungal use causes severe 'die-off' symptoms worse than the infection itself; treatment must be slow and steady to support liver and gut..

Aggressive antifungal use causes severe 'die-off' symptoms worse than the infection itself; treatment must be slow and steady to support liver and gut.

Supports

There is limited but emerging evidence that rapid killing of Candida with antifungals can trigger a Jarisch–Herxheimer–like “Candida die‑off” reaction, characterized by transient worsening of systemic symptoms shortly after treatment begins.^[11] One recent review on Candida die‑off describes that when large numbers of Candida cells are killed quickly by antifungals, they release toxic substances that may transiently worsen symptoms and increase detoxification load on liver and kidneys.^[11] Reviews of antifungal agents document that many systemic antifungals (azole class, amphotericin B, echinocandins) can cause hepatotoxicity ranging from asymptomatic liver enzyme elevations to clinically significant liver injury, supporting the need for liver monitoring and dose caution, especially with prolonged or high‑dose therapy.^[7][8][17] Educational and review sources on Candida die‑off and Jarisch–Herxheimer reactions recommend adjusting the pace of antifungal escalation and providing supportive care (hydration, monitoring, temporary dose reduction) if significant die‑off symptoms occur, which is broadly consistent with a “slow and steady” clinical approach in susceptible patients, although this is based largely on expert opinion and case‑level evidence rather than randomized trials.^[11]

Contradicts

High‑quality randomized trials and major infectious disease guidelines do not describe die‑off reactions to antifungal therapy as being predictably “worse than the infection itself” or as a typical or expected outcome of appropriate antifungal dosing; instead, they treat Jarisch–Herxheimer–type reactions in fungal disease as rare or anecdotal phenomena rather than a central feature of therapy. The Candida die‑off review itself acknowledges that the concept largely derives from mechanistic reasoning and limited clinical reports, not from large controlled trials, and evidence on its frequency, severity, and clinical impact remains sparse.^[11] Standard reviews of antifungal safety emphasize dose‑related toxicities (hepatotoxicity, gastrointestinal upset, QT prolongation, etc.) as the primary concern, not toxin‑mediated die‑off; these adverse effects are monitored and managed with usual pharmacovigilance and are generally considered uncommon and manageable when drugs are used at guideline‑recommended doses.^{[7][8][12][17]} No major guideline‑level evidence supports a blanket rule that antifungals must always be introduced very slowly to “support the liver and gut”; instead, dosing is primarily determined by infection severity, drug pharmacokinetics/pharmacodynamics, and patient comorbidities, with monitoring of liver function and other labs rather than routine under‑dosing to avoid presumed die‑off. Over‑emphasizing die‑off and undertreating serious fungal infection could increase the risk of persistent or progressive disease, which is contrary to guideline priorities. Overall, the claim that aggressive antifungal use commonly causes severe die‑off that is worse than the infection, and that slow titration is universally required, is not supported by robust clinical trial or guideline evidence.

Mainstream view

The mainstream medical position is that systemic antifungal therapy can sometimes cause Jarisch–Herxheimer–like worsening of symptoms (Candida die‑off) and can produce hepatotoxicity and gastrointestinal side effects, but these events are uncommon and usually short‑lived or manageable with standard monitoring and dose adjustment, not a reason to systematically avoid guideline‑appropriate dosing.^{[7][8][11][17]} For most fungal infections, especially invasive or systemic disease, clinicians prioritize rapid achievement of effective therapeutic concentrations to control the infection, while monitoring liver function tests and other safety parameters and modifying therapy if objective toxicity or intolerable side effects occur. Jarisch–Herxheimer reactions are well‑described primarily for spirochetal infections and are considered transient inflammatory responses that rarely outweigh the need for appropriate antimicrobial treatment.^[4] In practice, dose escalation may be individualized (for example in frail patients or those with prior adverse reactions), but major guidelines do not recommend universal “slow and steady” initiation of antifungals solely to prevent die‑off; rather, they emphasize appropriate drug choice, correct dosing, treatment duration, and routine safety monitoring as the evidence‑based approach to protecting liver and gut while effectively treating the infection.^{[7][8][13][17]}

In their own wordsWatch sourceArchived copy

“If you unleash a pile of antifungals before your liver and gut can keep up, you feel the die off harder than the candida itself. Slow and steady wins this one.”

Rule: RSMo § 331.010(1)